This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Jun 23;369(9579):2056-8.

doi: 10.1016/S0140-6736(07)60957-X.

Gene therapy for Parkinson's disease: early data

A Jon Stoessl¹

Affiliations

PMID: 17586286
DOI: 10.1016/S0140-6736(07)60957-X

Comment

Gene therapy for Parkinson's disease: early data

A Jon Stoessl. Lancet. 2007.

. 2007 Jun 23;369(9579):2056-8.

doi: 10.1016/S0140-6736(07)60957-X.

Author

A Jon Stoessl¹

Affiliation

¹ Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, BC, Canada V6T 2B5. jstoessl@interchange.ubc.ca

PMID: 17586286
DOI: 10.1016/S0140-6736(07)60957-X

No abstract available

PubMed Disclaimer

Comment on

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.
Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. Kaplitt MG, et al. Lancet. 2007 Jun 23;369(9579):2097-105. doi: 10.1016/S0140-6736(07)60982-9. Lancet. 2007. PMID: 17586305 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information